



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Difamilast

Item No. 39664

CAS Registry No.: 937782-05-3
Formal Name: N-[[2-[4-(difluoromethoxy)-3-(1-methylethoxy)phenyl]-4-oxazolyl]methyl]-2-ethoxy-benzamide
Synonym: OPA 15406
MF: C₂₃H₂₄F₂N₂O₅
FW: 446.4
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Difamilast is supplied as a solid. A stock solution may be made by dissolving the difamilast in the solvent of choice, which should be purged with an inert gas. Difamilast is soluble in acetonitrile and DMSO.

Description

Difamilast is an inhibitor of phosphodiesterase 4 (PDE4).¹ It is selective for the PDE4 isoforms PDE4A, PDE4B, PDE4C, and PDE4D (IC₅₀s = 0.0832, 0.0112, 0.2493 and 0.0738 μM, respectively) over PDE5A and PDE10A (IC₅₀s = 4.793 and 1.4346 μM, respectively) and eight other PDEs (IC₅₀s = >10 μM for all). Difamilast (0.01-10 μM) increases intracellular cAMP levels in U937 cells. It inhibits LPS-induced increases in TNF-α secretion from isolated human and mouse peripheral blood mononuclear cells (PBMCs; IC₅₀s = 19 and 3.5 nM, respectively). Topical application of difamilast (3% w/v) decreases ear thickness and CD3⁺ T cell, eosinophil, and neutrophil lesion infiltrates in a mouse model of 2,4,6-trinitrochlorobenzene-induced chronic allergic contact dermatitis. Formulations containing difamilast have been used in the treatment of atopic dermatitis.

Reference

1. Hiyama, H., Arichika, N., Okada, M., *et al.* Pharmacological profile of difamilast, a novel selective phosphodiesterase 4 inhibitor, for topical treatment of atopic dermatitis. *J. Pharmacol. Exp. Ther.* **386**(1), 45-55 (2023).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/08/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM